Genotype-Guided PPI Dosing for Acid Reflux
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Who Is on the Research Team?
Ruchir Puri, MD
Principal Investigator
University of Florida
Are You a Good Fit for This Trial?
This trial is for adults 18 or older who have been diagnosed with GERD and are scheduled for an endoscopy, where they must also be found to have erosive esophagitis.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Proton Pump Inhibitors
Trial Overview
The study compares two ways of dosing proton pump inhibitors (PPIs): one group gets doses based on their CYP2C19 genetic type, while the other receives standard PPI doses. The goal is to see which method heals esophagitis better.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
proton pump inhibitor dose based on CYP2C19 phenotypes
conventional proton pump inhibitor dose of Pantoprazole 40 mg once or twice daily
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.